Pfizer hoping for earlier Elrexfio use in RRMM after Phase III trial

Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug ...

Pfizer's blood cancer drug meets main goal in late-stage trial

April 29 () - Pfizer said on Wednesday its drug Elrexfio met the main goal in ‌a late-stage trial that tested the blood ...

Pfizer posts late-stage trial win for multiple myeloma therapy Elrexfio

Pfizer (PFE) announced on Wednesday that Elrexfio, a treatment for a type of blood cancer called multiple myeloma, reached the primary endpoint in a late-stage trial, raising prospects for the ...
Hosted on MSN

Pfizer’s Elrexfio shows strong late-stage trial results in myeloma

Pfizer’s multiple myeloma drug Elrexfio met its main goal in a late-stage trial, delivering a statistically significant and clinically meaningful improvement in progression-free survival over standard ...
Fierce Pharma

Pfizer looks to jump start Elrexfio with topline win in second-line myeloma

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...
NBC Washington

Pfizer, BioNTech Say Trial Data Shows COVID-19 Vaccine More Than 90% Effective

Pfizer and BioNTech announced Monday their coronavirus vaccine was more than 90% effective in preventing COVID-19 among those without evidence of prior infection, hailing the development as “a great ...
ksby

Pfizer submits Phase 1 results of COVID-19 vaccine booster trial to FDA for review

Pfizer on Monday announced it submitted data to the Food and Drug Administration regarding the results of Phase 1 trials for a potential COVID-19 vaccine booster shot. In a press release, Pfizer said ...